{"id":"sbv","safety":{"commonSideEffects":[{"rate":null,"effect":"Cardiotoxicity (QT prolongation, arrhythmias)"},{"rate":null,"effect":"Pancreatitis"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Arthralgia/myalgia"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sbv (sodium stibogluconate or related pentavalent antimony formulation) acts as a leishmanicidal agent through oxidative stress induction and inhibition of parasite glycolysis and fatty acid oxidation. The drug accumulates in infected macrophages and parasitophorous vacuoles, where it generates reactive oxygen species that damage parasite DNA and proteins, leading to parasite death.","oneSentence":"Sbv is a pentavalent antimonial compound that kills Leishmania parasites by generating reactive oxygen species and disrupting parasite metabolism.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:52:54.342Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Visceral leishmaniasis"},{"name":"Cutaneous leishmaniasis"},{"name":"Mucocutaneous leishmaniasis"}]},"trialDetails":[{"nctId":"NCT06011343","phase":"PHASE2, PHASE3","title":"Tofacitinib Associated With Meglumine Antimoniate in Cutaneous Leishmaniasis","status":"UNKNOWN","sponsor":"Hospital Universitário Professor Edgard Santos","startDate":"2023-10-01","conditions":"Cutaneous Leishmaniasis, American","enrollment":22},{"nctId":"NCT06000514","phase":"PHASE1, PHASE2","title":"Topical Sm29 in Combination With Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis.","status":"COMPLETED","sponsor":"Hospital Universitário Professor Edgard Santos","startDate":"2019-01-17","conditions":"Cutaneous Leishmaniasis, American","enrollment":20},{"nctId":"NCT04488939","phase":"PHASE4","title":"Restylane® Skinboosters™ Vital in the décolletage Region","status":"COMPLETED","sponsor":"Erevna Innovations Inc.","startDate":"2020-03-06","conditions":"Decolletage Rejuvenation","enrollment":33},{"nctId":"NCT03023111","phase":"PHASE3","title":"Miltefosine and GM-CSF in Cutaneous Leishmaniasis","status":"COMPLETED","sponsor":"Hospital Universitário Professor Edgard Santos","startDate":"2017-06-30","conditions":"Cutaneous Leishmaniasis","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1637,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Glucantime"],"phase":"phase_3","status":"active","brandName":"Sbv","genericName":"Sbv","companyName":"Hospital Universitário Professor Edgard Santos","companyId":"hospital-universit-rio-professor-edgard-santos","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sbv is a pentavalent antimonial compound that kills Leishmania parasites by generating reactive oxygen species and disrupting parasite metabolism. Used for Visceral leishmaniasis, Cutaneous leishmaniasis, Mucocutaneous leishmaniasis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}